Search This Blog

Monday, August 10, 2026

Fauci privately warned of miscarriage risk of COVID vax, publicly claimed no issues: new texts

  Dr. Anthony Fauci privately raised concerns that the COVID-19 vaccine could “theoretically” be linked to miscarriages in expectant mothers, despite having publicly insisted there were “no red flags” for pregnant women.

“I asked around a bit more and another issue came up that you need to be aware of,” wrote Fauci in a Jan. 25, 2021, text exchange with then-Centers for Disease Control and Prevention (CDC) Director Dr. Rochelle Walensky and Surgeon General Vivek Murthy.

“Since many people have significant cytokines storm and fever after the 2nd dose, this theoretically could be associated with miscarriage in the 1st trimester,” added the then-National Institute of Allergy and Infectious Diseases director.

Dr. Anthony Fauci testifying at a Senate hearing.
Dr. Anthony Fauci privately discussed concerns that the COVID-19 jab could “theoretically” be associated with miscarriages in mothers, despite having publicly affirmed there were “no red flags” for pregnant women.Bonnie Cash/UPI/Shutterstock

Fauci, Walensky and Murthy had been discussing whether the vaccine posed any risks to women who followed the two-shot regimen earlier or later in their pregnancies.

Walensky responded to Fauci that the first trimester issues he raised were “definitely a good point, [especially] after dose two.”

Days later, on Feb. 3, Fauci said during a question-and-answer livestream with the Journal of the American Medical Association (JAMA) that the FDA “found thus far, and we have to be careful, but thus far no red flags about that, about pregnant women.”

Months later, the Biden White House’s chief medical adviser also said, “tens and tens and tens of thousands of women who have been followed by the CDC, who have been vaccinated when they were pregnant, there’s no indication whatsoever that there’s any increase of any adverse issues in a pregnant woman who was vaccinated compared to a pregnant woman who wasn’t vaccinated … it’s pretty clear that pregnant women should get vaccinated.”

Text messages from Dr. Fauci discussing the COVID-19 vaccine and potential miscarriage risk.
Dr. Fauci’s private text messages where he discussed the miscarriage risk linked to COVID-19 vaccine.Chairmen Ron Johnson and Rand Paul

Other communications between Fauci, Murthy and Walensky also showed them weighing the potential risks of vaccination against the risks posed by SARS-CoV-2, the virus caused by COVID-19.

Murthy also mentioned he was “surprised to see WHO [World Health Organization] put out a strong like saying they do not recommend moderna [sic] in pregnant women.”

“That’s a strong statement to make and potentially quite damaging to public confidence among pregnant women,” he told Fauci and Walensky in a text from Jan. 26, 2021. 

The messages, released by Sens. Rand Paul (R-Ky.) and Ron Johnson (R-Wis.), were taken from more than 34,000 texts and 522 voicemails obtained by the Senate Homeland Security Committee last week from Fauci’s government-issued cell phone.

According to the Republican senators, just three contacts are listed in that phone but it is “too early to determine whether any data has been deleted.”

https://nypost.com/2026/08/10/us-news/fauci-warned-of-miscarriage-risk-linked-to-covid-vaccine-while-publicly-claiming-no-issues-newly-released-texts-show/

Mamdani ups Amazon fight, backs bill risking price hike as retailer threatens to move NYC ops

 New York City Mayor Zohran Mamdani is throwing his support behind controversial legislation that would force Amazon and other delivery giants to directly employ thousands of drivers — despite warnings the policy will force Amazon outside the five boroughs and lead to slower, more expensive deliveries.

Mamdani on Monday backed the Teamsters-supported Delivery Protection Act, which would bar companies from subcontracting core warehouse and delivery work at last-mile facilities and require workers to be directly employed by the facility operator.

“Corporations like Amazon build billion-dollar business models by insulating themselves from accountability through a system of exploitative subcontracting,” the mayor said in a statement.

He called the bill “common-sense regulation that protects delivery workers, safeguards the communities where these facilities operate and ensures that the corporations benefiting from workers’ labor are responsible for the consequences of their business practices.”

However, the legislation would foist an extra $664 per year on New York households to get their goods, according to a study by consultancy AKRF. 

“This law is just going to raise prices for consumers,” Business Council of New York State spokesperson Steve Smith told The Post on Monday.

Amazon, which works with more than 40 local Delivery Service Partners employing over 5,000 people in New York City, has warned that the legislation could prompt it to move delivery operations outside the city.

A retreat outside the city limits would result in deliveries that are not only significantly slower but also more costly, AKRF previously warned.

“We’re committed to creating good jobs, supporting our thousands of employees and local small business partners in New York City and providing fast, reliable delivery for New Yorkers,” Amazon spokeswoman Kelly A. Nantel told The Post.

“But as written, this legislation would directly undermine that commitment — threatening the small businesses that deliver to customers, putting the jobs of more than 5,000 of their employees at risk and forcing us to consider relocating delivery operations outside of the city.”

Opponents of the bill planned to mount their own show of force Monday, with package delivery workers and small-business owners planning a 1 p.m. press conference in East Harlem to urge city leaders to reject the measure.

The New York Delivers coalition said its members will gather at Thomas Jefferson Park to argue that Intro 518 threatens thousands of delivery jobs and small businesses while raising costs for New Yorkers.

The coalition claims as many as 10,000 city delivery jobs could be at risk if the legislation passes, including an estimated 3,500 last-mile delivery jobs in Harlem and four adjoining Council districts.

New York Delivers also said 82% of the last-mile delivery workforce does not have a college degree, and 84% is non-white. The group plans to feature delivery workers and small-business owners who say the legislation threatens their livelihoods.

The opposition event is scheduled for the same day that supporters of the Delivery Protection Act are stepping up pressure on the Council, sharpening the fight over legislation that would upend the subcontracting model used for last-mile deliveries in the city.

Rudy Cazares, a New York City native who operates an Amazon Delivery Service Partner and is also a FedEx contractor, told The Post the legislation would put him out of business.

“I would be shutting my business down. I have no business,” Cazares told The Post.

He said he currently employs roughly 130 people and hires more during peak times like the holidays. His drivers start at $23.75 an hour, with more experienced drivers earning as much as roughly $27 an hour, he said.

“All my employees are W2, either full time or part time with benefits, paying payroll taxes,” Cazares said.

He pushed back on the notion that companies like his merely provide a buffer between Amazon and its drivers, saying his company hires its own employees and operates its own vehicles.

“They control the sorting of the packages. They stage them for us. We pick them up and we go deliver them,” Cazares said of Amazon.

He acknowledged that Amazon pushes its delivery partners to find efficiencies, including through technology, but argued that city officials should address concerns about the system without eliminating the businesses themselves.

“There’s been no dialogue that includes the small businesses that are the ones making this happen,” Cazares said.

“This direct hire mandate will eliminate every small business out there that delivers packages for any business,” he added.

City officials have also urged caution over the measure.

“We want to make sure we don’t have unintended consequences,” Carlos Ortiz, deputy commissioner of external affairs for the Department of Consumer and Worker Protection, said at an April Council hearing.

A spokesperson for Council Speaker Julie Menin previously said the Manhattan Democrat was waiting for the “bill to go through the legislative process, to receive input and engagement from stakeholders.”

“Amazon will say or do whatever it takes to deny workers stronger rights and wages and abdicate its responsibilities for its own employees, which is why journalists are obliged to expose these greedy corporate tactics and not serve as stenographers for the company’s anti-worker propaganda,” Matt McQuaid, a spokesperson for the Teamsters union, told The Post.

“With the rise of e-commerce, last-mile delivery facilities for shipping and logistics businesses have become an increasingly essential part of the infrastructure that keeps New York City running,” a FedEx spokesperson told The Post.

“FedEx is aware of the proposed bill and is working with the New York Delivers coalition. Any questions on the legislation can be directed to them.”

https://nypost.com/2026/08/10/business/nyc-mayor-mamdani-backs-amazon-delivery-worker-bill-escalating-fight-with-retail-giant/

Veru fully enrolls Phase 2b obesity trial, extends cash runway beyond 2027 interim analysis

 

Veru fully enrolls 239-patient Phase 2b PLATEAU obesity trial, extends cash runway beyond 2027 interim analysis

  • For fiscal Q3 2026, Veru reported non-GAAP EPS -$0.30 on revenue $0, beating EPS and revenue estimates.
  • Company remains pre-revenue, loss-making and pre-commercial, dependent on successful enobosarm obesity development and ongoing external financing.
  • Revenue, EPS and product sales were not disclosed, reinforcing the company’s early-stage, pre-commercial status.
  • Net loss was $7.0m, slightly better than $7.3m in the prior quarter.
  • R&D rose to $4.4m from $3.0m, driven by PLATEAU obesity trial enrollment.
  • G&A fell to $3.4m from $5.0m, mainly due to lower stock-based compensation.
  • Cash increased to $23.9m from $15.8m, extending runway beyond the PLATEAU interim analysis.
  • Novo Nordisk is supplying Wegovy free for PLATEAU and holds right-of-first-negotiation on combinations.
  • New U.S. method-of-use patent for enobosarm-semaglutide combination therapy extends intellectual property protection to 2044.
  • PLATEAU Phase IIb obesity trial has a 32-week interim readout expected in Q1 2027.
  • Targeting older Medicare obesity patients; management is optimistic on July 2026 Medicare GLP-1 coverage decision.
  • Main concern remains limited cash runway and high dependence on successful PLATEAU enobosarm trial outcomes.
  • Mixed quarter, driven by continued R&D investment and strategic progress in the enobosarm obesity program.

Q2 earnings beat, raised 2026 guidance, and $100M buyback ignite LFST

 

 11.5% surge

  • LifeStance reported Q2 revenue of $435.4M, +26% YoY and beating estimates of ~$415M (per earnings release and MarketBeat).
  • Turned profitable with net income $23.6M vs prior-year loss; Adj. EBITDA surged 94% to $66M (15.2% margin).
  • Clinician base grew 11% to 8,542; visit volumes rose 19% to 2.6M, showing strong operational momentum.
  • Raised full-year 2026 outlook for revenue ($1.685-1.725B), Center Margin, and Adj. EBITDA ($215-235M).
  • Announced new $100M share repurchase program, signaling board confidence in valuation and cash flow ($88M FCF in Q2).
  • Analysts responded positively (e.g., BTIG raised PT to $16 from $15, Maintain Buy); stock broke to new highs on continued buying.
  • Modest initial reaction post-Aug 6 release gave way to momentum buying and estimate revisions by Aug 10.

Nutex Health Q2 earnings beat and cost cuts drive surge

 

Nutex Health Q2 earnings beat and cost cuts drive 16% surge

  • Q2 net income swung to $65.8M (EPS $9.38) from prior-year loss; six-month net income surged 3100% to $112.6M (EPS $15.87).
  • Massive $52.3M reduction in contract services expense from retroactive HaloMD agreement amendment and lower CMS fees boosted profits.
  • Revenue normalized lower (Q2 -13.6% YoY to ~$211M) after 2025 IDR windfall, but hospital visits grew 9.6% YoY.
  • Strong first-half operating cash flow reached $109.7M; ended period with $205M cash and low debt of $31M.
  • Company reiterated plans to open three new micro-hospitals later in 2026, highlighting growth pipeline.
  • Positive digestion of Aug 6 after-hours release and Aug 7 call continued into Aug 10 trading, lifting shares ~16% intraday.

Oruka Q2 2026 net loss $41.2M (EPS -0.55) and $1.1B cash funds operations through BLA filing

 

Oruka Therapeutics Q2 2026 net loss $41.2M (EPS -0.55) and $1.1B cash funds operations through ORKA-001 BLA filing

  • Non-GAAP EPS was -0.55 in Q2 2026, down 20% YoY and missing EPS estimates
  • Q2 2026 revenue was $0, beating revenue estimates

Embecta beats Q3 2026 estimates and raises EPS and margin guidance despite U.S. revenue pressure

 


  • Q3 2026 non-GAAP EPS $0.56, down 50% YoY, but ahead of analyst estimates.
  • Q3 revenue $272 million, down 8% YoY, but strong sequential rebound.
  • U.S. revenue down 24.6% YoY on pricing, mix, and insulin pen weakness.
  • International revenue up 9.7% constant currency, led by Latin America and Asia.
  • Adjusted gross margin fell to 58.2% from 67.2% on lower U.S. volume.
  • Raised FY26 adjusted operating margin guidance to 23.5–24% on cost optimizations.
  • Raised FY26 adjusted EPS outlook to $1.80–$1.90, reaffirmed revenue guidance range.
  • Closed Owen Mumford acquisition; early contribution aided revenue and supports auto-injector expansion.
  • Deleveraging continues with $53 million debt repaid and $41 million free cash flow.
  • Management sees stable U.S. share but monitors ACA, Medicaid, and GLP-1 impacts.
  • Investors focused on U.S. recovery durability and timing of Aidaptus auto-injector ramp.
  • Main concern: Persistent U.S. volume and pricing pressure amid GLP-1 adoption and payer shifts.
  • Mixed quarter, driven by international strength, cost controls, and ongoing U.S. softness.